The Tri-Viral Synergy of EBV, HPV and HIV in Non-AIDS-Defining Cancers

Abstract

Epstein-barr virus (EBV) and human papillomavirus (HPV) are among the highly prevalent oncogenic viruses. Both can dodge host immune surveillance and reprogram cellular signaling to produce malignancy. For PLWH, long - term immune suppression and steady inflammation amplify these effects, leading to an increasing prevalence of non–AIDS-defining cancers (NADCs). This paper looks into the molecular and immunological interactions among EBV, HPV, and HIV that bring about viral-driven oncogenesis. Latent proteins, including LMP1 and EBNA, modify NF-κB and JAK/STAT pathways to increase the level of proliferation and block apoptosis. Meanwhile, HPV oncoproteins E6 and E7 break p53 down and inactivate pRb to induce genomic instability. CD4+ T-cell depletion stemming from HIV and dysregulated cytokine profiles make viral persistence and co-infection synergy possible. Epidemiological and molecular data imply that EBV–HPV coinfection causes more aggressive tumor behavior and a worse prognostic scenario, especially in immunocompromised hosts. All things considered, this study emphasizes how the interaction of EBV, HPV, and HIV forms a joint oncogenic network that sustains viral persistence, evades the immune system's control, and hastens the transformation into a malignant state. Grasping this triviral synergy is essential for bettering cancer prevention and management strategies among PLWH. Comprehending this three-virus cooperation is essential for bettering cancer prevention and management strategies for PLWH.